SLD 2435
Alternative Names: SLD-2435Latest Information Update: 26 May 2022
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; Natural killer cell stimulants; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer